Iterum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Signs Agreement with Eversana for U.S. Commercialization of ORLYNVAHTM
Iterum Therapeutics plc has announced a significant agreement through its subsidiary, Iterum Therapeutics US Limited, with EVERSANA Life Science Services, LLC for the commercialization of ORLYNVAHTM in the United States. Under this agreement, Eversana will provide a comprehensive range of services, including sales, marketing, logistics, and regulatory support, among others, to facilitate the US launch and distribution of the product. This partnership is set to last until five years post-commercial launch, with provisions for termination under specific conditions. Iterum will retain responsibility for legal, regulatory, and manufacturing aspects while Eversana will be the exclusive provider of the agreed-upon services, ensuring compliance with applicable laws.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iterum Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-084650), on June 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。